The RETT REVOLUTION trial is a placebo-controlled, single-blinded, exploratory study with patients serving as their own control ("N of 1" trial design) where the safety and efficacy of vorinostat in the treatment of Rett syndrome will be evaluated. Each patient will be self-controlled in an adapted N-of-1 study design methodology by using a 4-week placebo baseline. Vorinostat dose escalation will occur every 8 weeks of daily dosing: placebo, 80mg/m2/day, 160mg/m2/day.
Key study objectives will include:
* To confirm the safety and tolerability of oral vorinostat 80mg/m2/day and 160mg/ m2/day dose levels when administered to typical Rett patients
* To identify the nature and magnitude of treatment response to vorinostat, as measured by changes in clinical and laboratory parameters indicative of trend towards benefit, as well as changes in mRNA expression (transcriptome response)
* Provide a data-driven justification for future study design and statistical analysis plan for subsequent clinical studies assessing safety and efficacy of vorinostat in Rett syndrome

开始日期2025-10-15

申办/合作机构

Unravel Biosciences, Inc.

NCT07150026

/ Not yet recruiting临床1期

An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome Using an "N of 1" Study Design

The study is an exploratory evaluation of the safety and efficacy of vorinostat in Pitt Hopkins syndrome. Each patient will be self-controlled in an adapted N-of-1 study design methodology with three treatment arms, including a 4-week placebo phase and two vorinostat dose arms, including every 8 weeks of daily dosing at a low dose of 80mg/m2/day and 8 weeks of a higher dose at 160mg/m2/day.
Key objectives of the study include:
* To confirm the safety and tolerability of oral vorinostat 80mg/m2/day and 160mg/ m2/day dose levels when administered to PTHS patients
* To identify the nature and magnitude of treatment response to vorinostat, as measured by changes in clinical and laboratory parameters indicative of trend towards benefit, as well as changes in mRNA expression (transcriptome response)
* Provide a data-driven justification for future study design and statistical analysis plan for subsequent clinical studies assessing safety and efficacy of vorinostat in PTHS

开始日期2025-10-15

申办/合作机构

Unravel Biosciences, Inc.

NCT06995521

/ Not yet recruiting临床2期IIT

Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation

This is a single-arm, open label, phase 2 study to determine the safety and efficacy of vorinostat without serotherapy as GVHD prophylaxis when combined with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate in patients aged 1 to 26 years of age with non-malignant disorders undergoing bone marrow transplant following myeloablative conditioning.

开始日期2025-08-01

申办/合作机构

University of Michigan

100 项与伏立诺他相关的临床结果

登录后查看更多信息

100 项与伏立诺他相关的转化医学

登录后查看更多信息

100 项与伏立诺他相关的专利（医药）

登录后查看更多信息

5,753

项与伏立诺他相关的文献（医药）

2025-12-31·AUTOIMMUNITY

Deciphering distinct pathogenic mechanisms of ankylosing spondylitis and systemic sclerosis via shared biomarkers ZSWIM6 and CCL3L3: Insights from an integrative bioinformatics approach

Article

作者: Zhou, Chenxing ; Zhan, Xinli ; Chen, Jiarui ; Xue, Jiang ; Shi, Jianjun ; Zhou, Zhongxian ; Yang, Renbang ; Huang, Liangyu ; Huang, Chengqian ; Liu, Chong ; Chen, Tianyou ; Feng, Sitan ; Huang, Jieping ; Wu, Shaofeng ; Zhu, Jichong

Ankylosing Spondylitis (AS) and Systemic Sclerosis (SSc) are both autoimmune diseases, albeit with distinct anatomical targets. AS primarily affects the spine and sacroiliac joints, triggering inflammation and eventual fusion of the vertebrae. SSc predominantly impacts the skin and connective tissues, leading to skin fibrosis, thickening, and potential damage to vital organs such as the lungs, heart, and kidneys. Despite their differing anatomical manifestations, inflammation serves as a pivotal factor in both conditions. Exploring the causes of the different pathogenesis of inflammation in AS and SSc could provide new insights into their treatment. We selected RNA-seq profiles of peripheral blood mononuclear cells (PBMCs) from the GEO datasets GSE73754 and GSE19617. DEGs were identified using the Limma R package with an adjusted p-value cutoff of < 0.05. Gene Ontology pathway analysis, SVM recursive feature elimination, and Gene Set Enrichment Analysis (GSEA) were conducted to analyze the DEGs. CIBERSORT was applied to estimate immune cell composition and its correlation with hub genes. Single-cell RNA sequencing data from peripheral blood mononuclear cells in the GSE194315 dataset were included to support differential expression analysis and biomarker identification. Additionally, single-cell RNA sequencing data from bone marrow blood samples were utilized to further validate these findings, offering complementary insights into biomarker expression across distinct sample types. A total of 762 DEGs were identified between AS patients and controls, and 441 DEGs between SSc patients and controls. Both conditions showed enrichment in the Natural killer cell mediated cytotoxicity pathway. ZSWIM6 and CCL3L3 were identified as potential biomarkers in AS and SSc, with significant diagnostic capabilities demonstrated by ROC analysis. Correlation analysis revealed associations between these biomarkers and specific immune cell types. The study utilizing ZSWIM6 and CCL3L3 as potential biomarkers provides deep insights into the distinct molecular mechanisms of SSc and AS. These findings lay the foundation for future research on targeted therapies and enhance our understanding of immune cell interactions in these autoimmune diseases.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab

Article

作者: Kim, Youn H. ; Akilov, Oleg ; Bagot, Martine ; Scarisbrick, Julia ; Ristuccia, Robert ; Wu, Wende ; Dwyer, Karen ; Foss, Francine

PURPOSE:

Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.

MATERIALS AND METHODS:

This post-hoc analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.

RESULTS:

A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vs. vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 vs. 3.1 months; p < 0.0001) in mogamulizumab vs. vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT vs. vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.

CONCLUSIONS:

MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors

Article

作者: Huang, Yudan ; Ding, Xueyan ; Liu, Jieqing ; Ma, Junjie ; Yuan, Dandan ; Liu, Han ; Gao, Yali ; Li, Jin ; Xia, Lin ; Deng, Changchun ; Dai, Wenqi ; Wu, Xingye

Herein, we firstly reported a series of biphenyl compounds bearing hydroxamic acid moiety as PD-L1/class I HDACs dual inhibitors. Among them, compound 14 displayed the strongest inhibitory activity in vitro against HDAC2 and HDAC3 with IC₅₀ values of 27.98 nM and 14.47 nM, and had an IC₅₀ value of 88.10 nM for PD-1/PD-L1 interaction. Importantly, 14 could upregulate the expression of PD-L1 and CXCL10 in a PD-L1 low-expression cancer cell line (MCF-7), highlighting the potential to enhance efficacy by recruiting T-cell infiltration into TME and improving the response of PD-1/PD-L1 inhibitor associated with PD-L1 low-expression. Besides, we identified another compound, 22, which possessed the strongest inhibitory activity against PD-1/PD-L1 interaction with an IC₅₀ value of 12.47 nM, and effectively inhibited the proliferation of three cancer cell lines. Our results suggest that compounds 14 and 22 can be served as lead compounds of PD-L1/class I HDACs dual inhibitors for further optimisation.

项与伏立诺他相关的新闻（医药）

2025-08-20

·PRNewswire

HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight

The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma, representing a potential expansion into solid tumors. Quisinostat (Viriom) is in Phase II for uveal melanoma, and Entinostat, partnered between EOC Pharma and Syndax, is being explored in Hodgkin lymphoma. LAS VEGAS, Aug. 20, 2025 /PRNewswire/ -- DelveInsight's HDAC Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Multiple Myeloma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Amyotrophic Lateral Sclerosis (ALS), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging HDAC inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the HDAC Inhibitors Market Report As per DelveInsight's analysis, the total market size of HDAC inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Multiple Myeloma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Amyotrophic Lateral Sclerosis (ALS), and others. Leading HDAC inhibitor companies, such as Xynomic Pharmaceuticals, Viriom, EOC Pharma, Syndax Pharmaceuticals, Jubilant Therapeutics, and others, are developing novel HDAC inhibitors that can be available in the HDAC inhibitors market in the coming years. Some of the key HDAC inhibitors in the pipeline include Abexinostat, Quisinostat, Entinostat, JBI-802, and others. Discover which indication is expected to grab the major HDAC inhibitors market share @ HDAC Inhibitors Market Report HDAC Inhibitors Overview Histone deacetylases (HDACs) remove acetyl groups from both histone and non-histone proteins. Because acetylation of histones is linked to an open chromatin structure and active gene transcription, HDAC activity leads to histone deacetylation and epigenetic suppression of gene expression. Since HDACs influence many pathways involved in cancer development, HDAC inhibitors (HDACis) show clinical effects through several mechanisms, including changes in gene expression of cell cycle and apoptotic proteins, acetylation of other proteins involved in cell growth and survival, effects on angiogenesis, aggresome formation, and DNA repair. There are 18 known HDACs, divided into two major groups and four classes based on their cellular location, homology, enzyme mechanism, sequence of discovery, and histone substrate specificity. The first group includes zinc-dependent HDACs, which all share a similar catalytic core for deacetylating acetyl-lysine residues. These comprise Class I (HDAC1, -2, -3, -8), Class II (IIa: HDAC4, -5, -7, -9; IIb: HDAC6, -10), and Class IV (HDAC11). The second group includes Class III HDACs (sirtuins, SIRT1–7), which rely on NAD+ for their enzymatic activity. HDAC Inhibitors Epidemiology Segmentation The HDAC inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases of Selected Indications for HDAC Inhibitor Total Eligible Patient Pool of Selected Indications for HDAC Inhibitor Total Treated Cases of Selected Indications for HDAC Inhibitor HDAC Inhibitors Treatment Market Several HDAC inhibitors are currently available on the market. Recent entrants include DUVYZAT (givinostat), while earlier approved drugs include BELEODAQ (belinostat), HIYASTA (tucidinostat), among others. DUVYZAT is a histone deacetylase inhibitor approved for treating Duchenne muscular dystrophy (DMD) in patients aged 6 and above. While it is categorized as an HDAC inhibitor, its exact mechanism of action in DMD is not fully understood. In April 2025, Italfarmaco announced that the CHMP of the European Medicines Agency (EMA) issued a positive opinion on DUVYZAT. The drug is also being evaluated in other indications: Phase III trial in Becker muscular dystrophy (BMD) and Phase II trial in polycythemia vera. HIYASTA (HBI-8000) is an epigenetic immunomodulator approved for several indications, including use as monotherapy for certain subtypes of relapsed or refractory T-cell non-Hodgkin's lymphoma, specifically adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL) in Japan. HUYABIO International is conducting a multinational Phase III trial evaluating HIYASTA in combination with nivolumab for previously untreated metastatic or unresectable malignant melanoma. HIYASTA is an oral HDAC Class I inhibitor that induces cell cycle arrest and apoptosis in tumor cells, which underlies its efficacy in lymphoma. In September 2020, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation (ODD) to HIYASTA for relapsed/refractory ATL, and in December 2015 for PTCL. In June 2021, HUYABIO also received regulatory approval in Japan for HBI-8000 as monotherapy for relapsed/refractory ATL. Key Emerging HDAC Inhibitors and Companies Xynomic Pharmaceuticals (Abexinostat), Viriom (Quisinostat), EOC Pharma/Syndax Pharmaceuticals (Entinostat), Jubilant Therapeutics (JBI-802), and several other companies are currently engaged in the development and production of HDAC inhibitors, which have the potential to significantly impact and enhance the HDAC inhibitors market. Abexinostat, an oral, broad-spectrum HDAC inhibitor originally developed by Pharmacyclics and later licensed by Xynomic Pharmaceuticals in 2017, has demonstrated encouraging activity in both blood cancers and solid tumors. The drug is currently being studied in several Phase I to III clinical trials worldwide. In September 2019, Xynomic announced that the FDA had granted Fast Track Designation (FTD) to abexinostat as a monotherapy for fourth-line treatment of relapsed or refractory follicular lymphoma. The FDA had previously granted FTD for abexinostat in combination with pazopanib for first- or second-line therapy in renal cell carcinoma. Additional Phase II trials are underway in indications such as Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma. Quisinostat is another potent, selective oral pan-HDAC inhibitor, initially developed by Janssen Pharmaceuticals. HDAC inhibitors work by inducing cell cycle arrest, promoting differentiation, and triggering apoptosis in various human cancer cell lines. By inhibiting histone deacetylase, they increase acetylation of histone proteins, resulting in a more transcriptionally active chromatin state and altered gene expression involved in proliferation, apoptosis, and differentiation. Multiple preclinical studies and Phase I/II trials have evaluated quisinostat's safety and effectiveness, showing promising anti-tumor effects in several advanced and treatment-resistant cancers — including platinum-resistant ovarian cancer (in combination with paclitaxel and carboplatin), uveal melanoma, and synovial sarcoma. The anticipated launch of these emerging therapies are poised to transform the HDAC inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HDAC inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about HDAC inhibitors clinical trials, visit @ HDAC Inhibitors Treatment Recent Developments in the HDAC Inhibitors Space In May 2025, Amylyx Pharmaceuticals announced positive Week 48 data from the Phase II open-label HELIOS clinical trial of AMX0035 in adults living with Wolfram syndrome. In May 2025, the University of Miami, in collaboration with Viriom, initiated a Phase II clinical trial in the US (NCT06932757) to evaluate an oral therapy for patients with uveal melanoma who have undergone at least one prior line of treatment. In April 2025, Xynomic Pharmaceuticals concluded a Phase I/II clinical trial in the United States (NCT03939182), evaluating a combination oral therapy for patients with Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma who had received at least one prior line of treatment. Discover more about HDAC inhibitors in development @ HDAC Inhibitors Clinical Trials HDAC Inhibitors Market Dynamics HDAC inhibitors are a class of epigenetic drugs that modify gene expression by altering chromatin structure. Initially developed as anticancer agents, they have shown significant therapeutic potential in various malignancies, especially hematologic cancers like T-cell lymphoma and multiple myeloma. The market initially gained traction with FDA approvals of drugs such as Vorinostat, Romidepsin, and Panobinostat. Their unique mechanism of action targeting epigenetic regulation drew interest as precision medicine and oncology research grew, driving pharmaceutical investment in this segment. The HDAC inhibitors market continues to expand largely due to the rising prevalence of cancer worldwide and the need for more targeted therapies with better safety profiles. Additionally, ongoing clinical trials are exploring HDAC inhibitors in combination with other therapies, such as immune checkpoint inhibitors, proteasome inhibitors, and traditional chemotherapeutics. These combination approaches aim to overcome resistance and enhance efficacy, creating more opportunities for market growth. As more data emerges demonstrating synergistic benefits, partnerships between biotech startups and large pharmaceutical firms are accelerating further development. Despite this positive outlook, the market faces several challenges. Many HDAC inhibitors are associated with toxicity issues such as fatigue, gastrointestinal disturbances, and thrombocytopenia, which limit broader adoption. Competition from newer targeted therapies and immuno-oncology drugs also puts pressure on the HDAC inhibitor segment. Moreover, several compounds failed in late-stage trials due to a lack of efficacy, leading to cautious investor sentiment and prioritization of combination rather than monotherapy approaches. Looking ahead, the market dynamics are expected to be shaped increasingly by precision oncology trends and biomarker-driven patient selection, allowing more effective targeting of responders. If safety profiles can be improved and combination regimens continue to show strong results, HDAC inhibitors will retain a meaningful role in the evolving oncology landscape. Novel formulations, selective HDAC isoform inhibitors, and expansion into non-oncology indications such as neurodegenerative or inflammatory diseases may further diversify the market and drive its next phase of growth. Learn more about the HDAC inhibitors @ HDAC Inhibitors Analysis Scope of the HDAC Inhibitors Market Report HDAC Inhibitors Therapeutic Assessment: HDAC Inhibitors' current marketed and emerging therapies HDAC Inhibitors Market Dynamics: Conjoint Analysis of Emerging HDAC Inhibitor Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, HDAC Inhibitors Market Access and Reimbursement Table of Contents Related Reports Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others. Amyotrophic Lateral Sclerosis Market Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALS companies, including AB Science, Alector, GSK, Brainstorm Cell Therapeutics, Ionis Pharmaceuticals, Medicinova, Denali Therapeutics, AbbVie, Calico Life Sciences, Clene Nanomedicine Biosciences, Seelos Therapeutics, Prilenia Therapeutics, Rapa Therapeutics, Neurosense Therapeutics, Helixmith, Transposon Therapeutics, Revalesio Corporation, Annexon Biosciences, Corcept Therapeutics, AL-S Pharma, Sanofi, Denali Therapeutics, Orphai Therapeutics, among others. Peripheral T-cell Lymphoma Market Peripheral T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others. Cutaneous T-cell Lymphoma Market Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Pfizer, Helsinn Therapeutics, Kyowa Hakko Kirin, Citius Pharmaceuticals, Soligenix, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, BioInvent International AB, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床3期快速通道孤儿药免疫疗法

2025-08-18

·求实药社

年度医药人盘点：63位CNS领域创始人&CEO盘点（最新）

中枢神经系统（CNS）一直是医学研发中最具挑战性的领域之一。从阿尔茨海默病到精神分裂症，从神经退行性疾病到罕见脑病，CNS 疾病不仅深刻影响患者生活质量，也持续推动全球医疗科技的创新突破。为便于行业观察与交流，本文汇总整理了63位深耕CNS领域的企业创始人及CEO（排名不分先后）。所列信息来自公司官网及公开资料，如有更新滞后，敬请谅解。【上篇】见文末 33、刘毅，复星医药，首席执行官兼总裁刘毅先生，1975年8月出生，中国国籍。刘毅先生于2015年11月加入本集团，现任本公司首席执行官兼总裁、医疗器械事业部董事长兼首席执行官、医学诊断事业部董事长；并于本公司若干控股子公司担任董事、管理层职务，其中包括于香港联合交易所有限公司上市公司Sisram Medical Ltd（股份代码：01696）任执行董事、董事会主席。刘毅先生拥有北京理工大学工学学士学位、北京大学管理学硕士学位及北京航空航天大学生物医学工程博士学位。 34、龙爱晶，翼思生物， CEO • 25年跨国药企管理经验 • 前赛诺菲中国区中枢神经（CNS）事业部总经理，创建中国外资药企最大 CNS 事业部 • 曾任职于诺华、百时美施贵宝、惠氏等一线跨国药企，覆盖市场营销、医学事务及事业部管理等全商业化管理经验 • 北京协和医科大学医学博士、中欧国际工商学院管理学硕士 35、陆英明，辉大基因，首席执行官及联合创始人拥有逾30年的全球药物开发、基因/细胞治疗药物、生物药物和罕见病相关经验，曾服务于多家知名生物技术/生物制药公司，包括上海复宏汉霖、Spark Therapeutics（被罗氏收购）、百健（Biogen）和拜耳医药保健（Bayer）等。在药品注册领域拥有丰富实践经验，在北美/南美、欧洲、印度、南非、巴西、阿根廷和亚太地区，成功提交超过250份IND、NDA/BLA和MAA，先后领导或参与了21个获批产品从临床开发到产品批准上市全过程，成绩斐然。已在广获认可的同行评审期刊上发表了100多篇学术论文及书籍章节，包括《新英格兰医学杂志》、《自然医学》、《自然》、《细胞》、《科学》和《血液》。拥有美国哈佛商学院MBA学位，并于加州大学旧金山分校医学院获得神经科学博士学位和美国临床研究认证资质。 36、吕佳声，润佳医药，创始人、CEO 近15年的药物研究经验，主导了多个1类创新药项目，系数个临床药物化合物发明人。其中，阿尔兹海默症的新药项目处于美国三期临床研究中（孤儿药、快速审批）。现兼任复旦大学生命科学院博士生导师、中国科学院深圳先进技术研究院研究员。 37、孟夏，艾码生物，CEO兼联合创始人孟夏博士毕业于巴黎第六大学，在法国国立医学科学院(法国NIH)和居里研究所具有10+年基础研究经历，在Clinical Cancer Research、PNAS、PLoS One等国际著名学术杂志发表30余篇文章。孟夏博士还具有20余年生物技术研发、市场、商务和管理工作经历，多年从事生物创新药的开发工作，曾领导团队完成3个病毒为载体的一类创新药的研发，并获批进入临床。孟夏博士曾任在多个跨国企业任中国区总经理、首席运营官、董事总经理等高管职位。 38、莫丁丁，北京光脑生物科技有限公司，创始人&CEO 北京光脑生物科技有限公司（简称“光脑生物”）创始人莫丁丁是德国明斯特大学生物学博士、德国马克斯·普朗克衰老生物学研究所博士后，获评北京市海外高层次人才、深圳市海外高层次人才（孔雀计划）。 39、任晋生，江苏先声药业有限公司，董事长兼首席执行官任晋生先生为先声药业创始人，现任集团董事长兼首席执行官，负责公司整体战略、业务运营，作出本集团的重大业务及运营决策。任晋生先生1982年毕业于南京中医药大学，后于南京师范大学获得工商管理硕士学位，获江苏省人力资源与社会保障厅认证为研究员（自然科研系列）以及高级经济师。国家科技进步二等奖获得者，现任中国医药创新促进会副会长、江苏省总商会副会长、南京市工商联副主席。 40、申华琼，纽欧申医药，创始人兼CEO 申华琼博士是美国精神病学和神经病学委员会认证的医生。她拥有印第安纳大学医学院生命科学博士学位，在那里她还完成了临床住院医师培训，以及内分泌学、精神药理学和临床药理学的三个博士后培训。进入工业界后，她先后陆续在美国礼来公司、惠氏公司和辉瑞公司担任中枢神经系统药物开发的临床项目负责人，并领导了让中国加入全球临床研发的倡导和实施。申华琼博士于2013年作为首席医学官加入恒瑞医药，建立创新药临床团队，成功帮助公司走向国际化。她随后又加入杨森制药，担任中国药物开发总负责。她于2017年加入天境生物任职至首席执行官，帮助打造研发团队和临床管线，为公司在纳斯达克成功IPO及其成长做出了重要贡献，与艾伯维的成功合作项目尤其令人瞩目。2022年1月，申华琼博士创办纽欧申医药有限公司，专注于CNS创新药研发。申华琼博士同时还是北京大学客座教授，以及印第安纳大学医学院兼职教授。在她的职业生涯中获得了众多的荣誉与认可，包括近期的业界权威媒体Endpoints News的2021年生物制药研发领域的20位杰出女性之一，福布斯2021年中国科技领域女性 50 强， 2022年百华协会年度唯一的女性领导者奖。 41、史艺宾，大睿生物，CEO、联合创始人 Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation and investment deals, including YHL Diagnostics (688575.SH), InventisBio (688382.SH), Keymed Bio (2162.HK), New Horizon Health (6606.HK), Burning Rock (BNR.N), Revolution Medicine (RVMD.N), Xihua Scientific Co, Singleron Biotechnologies, Pinnacles Dx, FutureGen, Regor Therapeutics, etc. Prior to LAV, Stella was new product planning lead for oncology at Roche overseeing development strategy for early stage pipeline products in China and Asia Pacific region. Previously, Stella worked with ZS Associates, a worldwide management consulting firm in healthcare industry, as a consultant. Stella holds a B.S degree in molecular biology from Fudan University. 42、舒东旭，舶望制药，董事长，CEO 舒东旭博士是舶望制药的联合创始人。舒博士曾任Arrowhead Pharmaceuticals高级科学家，专注于肝外递送平台的开发，其中一些已成功应用于临床研究。在加入Arrowhead之前，舒博士在美国西北大学进行了博士后研究。舒博士是北京大学化学系理学学士，美国威斯康星麦迪逊分校有机化学博士。 43、谭骏，安域生物，联合创始人/董事长/首席执行官CEO/医学博士/首席科学家复旦大学人类遗传学理学硕士,第三军医大学医学博士。2003年获中国国家自然科学基金海外优秀（杰出）青年科学家基金，2007年被授予Robert A. Silver发育神经生物学讲席教授（Robert A. Silver Endowed Chair），终身教授。在国际权威杂志发表原创学术论文约170篇（SCI），如《SCIENCE》、《Nature Neuroscience》、《Nature Communications》、《Nature Medicine》以及获得专利授权23项。主持和参与美国国立卫生研究院（NIH）等科研课题30余项。 44、王冰，麦科奥特，创始人、董事长兼总裁曾任西安交通大学教授生物药缓释关键技术研发中心主任和创始人重大新药创制专项、国家自然科学基金评审专家中国生物制品学杂志编委会委员中国药理学会心血管分会委员 45、王海盛，思合基因，创始人兼CEO 北京大学药物化学博士，师从中国寡核酸化学泰斗张礼和院士国家级高层次人才“万人计划”科技领军（2024）原哈药集团（600664）研发总裁；曾在保诺科技、百济神州、扬子江药业集团和哈药集团从事近20年创新药物研发和战略管理，主导获10余项国际创新药物批件主持/参与多项创新药物的项目，参与中国首款获FDA批准新药的研发工作获一类和三类新药临床批件及生产批件十余个；主持3项核酸药物临床前研究项目，曾负责科技部“十二五”重大新药创制项目。 46、王静，Myrobalan Therapeutics，联合创始人兼首席执行官自 2006 年以来，涵盖小分子药物开发从发现到商业化的所有阶段的行业经验。在 Curis、TESARO/GSK 和 Constellation 担任过各种研发领导职务。领导 ZEJULA™ 的 NDA/CDx 联合申报、生命周期管理和商业化的转化开发。哈佛医学院博士，论文研究重点是神经退行性变。 47、王青松，清普生物，创始人，CEO 中国药科大学博士，复旦大学硕士近20年新药研发管理和业务拓展经验，曾分管BD、临床、制剂业务 48、王晓东，维泰瑞隆，创始人、董事长王晓东博士是维泰瑞隆创始人兼董事长。他还共同创立了百济神州（纳斯达克股票代码：BGNE），是百济神州的董事会成员，并担任科学顾问委员会主席。王晓东博士是北京生命科学研究所（NIBS）的创始所长，自2010年以来一直担任该研究所所长和研究员。此前，他于1997年至2010年期间担任霍华德·休斯医学研究所的研究员，并于2001年至2010年在美国德克萨斯大学西南医学中心担任生物医学科学杰出首席教授。王晓东博士因其科学成就获得了多个奖项，包括美国化学学会颁发的礼来生物化学奖，美国生物化学和分子生物学学会授予的ASBMB-Merck奖，美国国家科学院的分子生物学奖和理查德·朗斯伯里奖，美国癌症研究协会颁发的杰出成就奖，以及邵逸夫生命科学与医学奖等。王晓东博士拥有美国德克萨斯大学西南医学中心生物化学博士学位和北京师范大学生物系学士学位。王晓东博士于2004年当选美国国家科学院院士，2013年当选中国科学院外籍院士。 49、王友鑫，上海璃道医药科技有限公司，董事长、联合创始人王友鑫，博士，现任上海璃道医药科技有限公司董事长、首席执行官。上海市青年创业英才、上海市扬帆计划人才、闵行区青年创业英才、华东理工大学药学硕士企业导师。 2011-2016年，在华东理工大学攻读药学博士学位。博士期间以第一作者身份在国际著名期刊Nat Chem Biol发表论文1篇，在药物化学一流期刊J. Med. Chem.发表论文2篇，申请发明专利4项。同时，项目研究成果成功实现产业转化，转让给国内上市医药集团进行进一步开发（转让费1500万）。 2016年，作为联合创始人成立上海璃道医药科技有限公司。公司成立后，作为公司研发负责人已经成功推动1个项目完成pre-IND申报，1个项目进入临床前研究阶段，多个项目确定PCC化合物，在新药研发方面积累了丰富的经验。以第一发明人的身份申请了3项PCT国际专利，9项中国发明专利，其中有5项已经授权；作为项目参与者在cell discovery发表论文1篇。先后获得上海市优秀毕业生、华东理工大学优秀学位论文奖、上海市新药设计重点实验室学术论文奖和“阿达玛斯”学术论文奖等荣誉。2018年入选“创新行动计划”上海市青年科技英才扬帆计划资助人员名单；作为项目负责人两次获得上海市科技型中小企业技术创新资金资助，且入围了第九届中国创新创业大赛国赛阶段；2019年在中共上海市委党校参加了上海市重点培育创业企业创始人培训班学习，并取得结业证书；2020年先后被认定为闵行区青年创业英才和上海市青年创业英才。 50、徐景宏，昌郁医药，董事长&CEO 哈佛医学院神经病学和眼科教授。波士顿儿童医院病毒核心主任。轴突再生、神经变性和髓鞘再生研究的世界领导者。美国国家医学科学院（NAM）院士。克林根斯坦神经科学研究员、约翰默克学者、麦克奈特学者、里夫-欧文研究奖章获得者。多伦多大学博士，加州大学旧金山分校 Marc Tessier-Lavigne 博士后研究。 Rugen 联合创始人（项目授权给 McQuade 战略研究与发展中心）。 51、颜光美，广州市赛普特医药科技有限公司，创始人、首席战略官；原中山大学副校长颜光美博士，药理学家，曾任中山医科大学副校长、中山大学副校长、党委书记。国家杰出青年基金和国务院特殊津贴获得者，教育部科学技术委员会学部委员。现任中山大学中山医学院药理学教授，博士生导师，教育部规划教材《药理学》主编。科研领域为抗脑卒中、抗癌症创新药物的研究和临床转化。 52、颜毅，青岛普美圣医药科技有限公司，联合创始人及CEO 北京大学生命科学学院生物技术系学士加拿大英属哥伦比亚大学医学院神经科学系硕士主要研究领域为神经系统突触可塑性的产生机制以及相关神经系统疾病的发病机理。对Akt在AMPA受体上膜以及由此导致的长时程增强效应(LTP)中的作用进行了深入研究，揭示出可能的Akt作用机制，为相关疾病治疗和药物开发提供了新的靶点和方向。此外，对神经肽及其受体在中枢神经系统中介导突触可塑性和痛敏反应的作用机制进行研究,为进一步阐明疼痛的产生机理揭示了可能的方向。除了多年的科学研究经历，还拥有成功的企业管理和运作经验，处事严谨负责，作风干练，善于沟通；在团队建设及企业文化建设等方面具有丰富经验。 53、杨士豹，南京宁丹新药技术有限公司，联合创始人国家1类新药先必新®的发明人及项目负责人曾任先声药业项目总监，先后主持7个新药品种的研发，多个产品已上市销售创办多家新药研发公司，多个品种已在国内外获得批件 54、俞磊，上海优卡迪生物医药科技有限公司，CEO&首席科学家俞磊博士现为上海优卡迪生物医药技术公司创始人；中国外籍专家、华师大生物医学工程和技术研究所创始人和所长；国际人类基因变异组项目中国区工作委员会委员；中国研究型学会细胞治疗专业委员会会员；上海市健康科技协会免疫大健康专业委员会主任；上海药剂专委会委员；上海医用材料专委会会员。主要研究方向为基因治疗和细胞治疗、靶向药物传递系统。30多年基因/细胞疗法研究开发经验、医、制药和和20多年年美国和国内的企业管理和运行经验。于2015年初成立上海优卡迪，专注CAR-T技术创新和免疫治疗产品开发，是国内CAR-T技术创新的领军企业，目前已经在国内外成功开展了1000多例的血液肿瘤和实体瘤的CAR-T治疗临床IIT研究。 55、张诚，祐儿医药，CEO 张诚先生是祐儿医药的创始人，也是商业化和产品引进方面的资深行业领袖，在中国医疗行业拥有超过20年的管理经验。在创立祐儿医药之前，张诚先生曾担任先声药业集团首席运营官，负责集团商业化团队的全面管理，集团数字化建设和公共事务，并作为主要成员参与领导了公司IPO；此前，曾服务于全球知名跨国制药企业默沙东，担任中国董事总经理，建立并领导了默沙东在中国的多个职能部门，取得了业务的高速增长。拥有南京大学理学学士及EMBA学位。 56、张金华，南京驯鹿医疗，联合创始人&CEO 张金华女士毕业于东北财经大学，法学硕士，资深证券律师，曾就职于投资银行和行业领先的证券律师事务所。作为项目主导人，兼任财务顾问和律师双重身份，曾主办几十家中国企业的上市和并购重组项目，包括国内A股改制上市、香港上市、美国纳斯达克上市、加拿大多伦多交易所上市项目。张金华女士自2003年后主办过近20个上市公司的并购重组业务，累计协助几十家企业完成境内外上市。2015年作为天使投资人投资了早期从事CAR-T研发的公司，并出任董事。 2017年，张金华女士创办驯鹿生物，以“专注创新生物疗法，为患者带来治愈的希望”为使命，致力于解决中国乃至全球患者未被满足的临床需求。在张金华女士的带领下，驯鹿生物已发展成为细胞与基因治疗领域的行业领军企业，具备从早期药物发现、临床研发、注册申报到商业化的全流程能力，同时公司还拥有业界一流的全人源抗体库平台，并于2023年成功上市了明星CAR-T产品福可苏®。入选2024“中国新药开拓奖20年·20人”；入选2024年《财富》中国最具影响力的商界女性榜单—未来榜。 57、张明奎，苏州新旭医药有限公司，创始人&CEO 新旭生技首席执行官 MD安德森癌症中心神经退行性疾病联盟，休斯顿葛兰素史克副总监，上海默克公司高级研究生物学家，波士顿西北大学和哥伦比亚大学神经生理学博士后波士顿大学药理学和神经科学博士台湾大学化学学士专业领域：神经退行性疾病；突触功能；新型生物标志物发现 58、张彦丰，AlaMab Therapeutics，共同创始人、总裁张彦丰博士于Michigan State University 获得遗传学/生物化学博士学位，并相继在Pacific Northwest National Laboratory和University of Texas Health Science Center at San Antonio进行博士后研究。在蛋白质结构和功能、抗体生产和抗体药开发方面有十多年的工业和学术界经验。在加入AlaMab之前，曾担任美国上市药企XBiotech公司抗体开发和生产工艺总监。张博士主要负责AlaMab的整体运营，临床前药物开发，包括抗体发现和成药性研究、生产和工艺开发、药理药效和毒理学研究等，并协调和管理相应的临床试验。 59、钟卫，威尚（上海）生物医药有限公司, 创始人、CEO 20年以上新型药物分子研发经验跨国药企项目负责人，领导团队新药研发 >30多篇文章发表于高影响杂志，会议和书最为》7家高影响杂志的审稿人是多个著名科学团的会员（ACS, SigmaXi, AACR, SDDA, SNO) 60、钟毅，北京卓凯生物，董事长、联合创始人，清华大学教授清华大学教授曾在冷泉港实验室担任教授神经生物学家 30年的学习记忆研究经验发现主动遗忘机制 61、周静敏，珠海鲸奇生物公司，联合创始人及CEO 周静敏，北京大学（前北医）本科，日本筑波大学博士，东京大学研究员，宾大Wistar研究所博后，在费城儿童医院开始参与细胞与基因治疗的临床试验。进入工业界后先后在罗氏礼来等药企担任高级研发管理工作，是美国药典委员会基因治疗专家组成员。 62、周显波，阿斯诺来（上海）医药科技有限公司，创始人&CEO 致力于阿尔茨海默和认知障碍的精准早发现和有效疗法的研发和开发。30+年生物医药研发，运营管理和多次创业经验。曾参与默沙东全球首创HDAC新药伏立诺他(Zolinza)的研发；领导美国达特神经科学公司药物研发部3年内为公司贡献３条CNS临床管线；创建昆明圣加南公司，领导开发数字化认知评估MemTrax产品；联合创建中泽医药开曼公司；创建阿斯诺来（上海）医药公司，全面负责阿斯诺来管线搭建和运营。 63、朱振东，科辉智药，创始人、董事长武汉工程大学学士，北京大学硕士，瑞士弗里堡大学博士，美国俄交俄州立大学/乔治敦大学博士后研究员。任新基首席研究员(PrincipalInvestigator)、AvilaTherapeutics 首席研究员(PrincipalInvestigator)、辉瑞制药首席科学家(Principal Scientist)。拥有逾20年计算机化学研发领域经验，擅长人工智能及云平台技术开发，擅长小分子化合物药物组合库设计，深度参与多个新药研发项目并成功进入临床阶段。 ▲年度医药人盘点：63位CNS领域创始人&CEO盘点（上篇）往期推荐 RECOMMEND 年度医药人盘点：40位ADC药企CEO盘点年度盘点：30位小核酸领域CEO资料整理！年度医药人盘点：70位小分子创新药企CEO盘点联系我们 ICNS 2025 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多！

高管变更

2025-08-07

·今日头条

抗癌新组合！温州医科大学团队发现两种药物协同抑制肺癌显奇效

【导读】阿达格拉西布是一种 KRASG12C 抑制剂，用于治疗经诊断为 KRASG12C 突变的非小细胞肺癌患者。尽管阿达格拉西布已展现出卓越的临床疗效和良好的安全性，但其抗肿瘤活性的分子机制仍不明确。近日，温州医科大学研究团队在期刊《Cell Death Discovery》上发表了研究论文，题为“Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer”，本研究报告称，阿达格拉西布治疗显著抑制了携带 KRASG12C 突变的细胞的生长，然而非 KRASG12C 细胞系 H1299 和 PC-9 对阿达格拉西布也敏感，这表明阿达格拉西布产生了脱靶效应。机制研究表明，阿达格拉西布治疗通过上调其泛素化水平降低了 NRF2 的水平，而 NRF2 过表达能够逆转阿达格拉西布诱导的 H23 和 H1299 细胞死亡。此外，阿达格拉西布治疗显著增加了 H23 和 H1299 细胞内的活性氧水平，从而激活了自噬和 AKT 信号通路。尤其是，阿达格拉西布与帕比司他联合使用在体外和体内均显示出增强的抗肿瘤活性。总之，本研究数据阐明了阿达格拉西布的一种新机制，这对阿达格拉西布的临床应用至关重要。 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41420-025-02657-9#Sec12 背景知识 01 KRAS是各种实体瘤中最常见的突变基因之一。在被诊断患有非小细胞肺癌（NSCLC）的患者中，约有 25% 的人存在 KRAS 突变，这些患者的预后通常不如没有这些突变的患者。长期以来，由于缺乏合适的结合位点，KRAS 被认为是药物开发中的一个难以攻克的目标。然而，随着强效 KRASG12C 抑制剂的发现，这种情况最近发生了改变。其中，索托拉西布和阿达格拉西布已显示出出色的抗肿瘤活性，并且最近获得了FDA的批准，用于治疗 KRASG12C 突变的 NSCLC 患者。这些批准标志着靶向这一特定肺癌亚型的靶向治疗取得了重要进展，为此前治疗选择有限的患者提供了新的希望。 ADA 与泊那替尼联合使用在非小细胞肺癌细胞中引发了显著的合成致死效应 02 上述研究结果表明，抑制 NRF2 在介导ADA的抗肿瘤功效方面至关重要。然而，这也会导致细胞补偿途径的激活，比如 AKT 通路，尤其是在高浓度时。鉴于 ADA 在极低浓度下就能显著抑制 ERK 通路，探索其与 NRF2 通路抑制剂的联合应用颇具意义。从鸦胆子植物中分离出的化合物鸦胆子苦醇是一种 NRF2 抑制剂。此外，组蛋白去乙酰化酶（HDAC）抑制剂如 MS-275、伏立诺他、贝利司他和帕比司他也能显著抑制 NRF2 以发挥其抗肿瘤活性。实际上，在用鸦胆子苦醇（BRU）、伏立诺他（VOR）或帕比司他（PAN）处理后，H23 细胞中 NRF2 的表达显著降低。细胞活力测定表明，这些药物显著提高了 H23 细胞对 ADA 的敏感性。为了加快临床应用，研究人员选择探究 PAN 与 ADA 的联合疗效及机制。联合指数结果表明，ADA 与 PAN 的组合在 H23 和 H1299 细胞中引发了显著的合成致死效应。蛋白质印迹法检测显示，在 H23 和 H1299 细胞中，联合治疗后 p-ERK 和 NRF2 的水平显著受到抑制。研究人员进一步探究了ADA和PAN联合用药的下游分子机制。蛋白质印迹法显示，ADA 或 PAN 处理后 LC3-II/I 的比例增加，而联合用药组中该比例增加更为显著。免疫荧光实验进一步证实，ADA 可与PAN协同激活 H23 和 H1299 细胞的自噬。值得注意的是，3-MA 能够有效阻断自噬激活以及联合用药在 H23 和 H1299 细胞中诱导的生长抑制作用，表明自噬在 ADA 和PAN的协同抗肿瘤活性中起关键作用。此外，NAC 预处理也减弱了 ADA 和PAN诱导的自噬激活和生长抑制作用。 ADA 与 PAN 联合使用在非小细胞肺癌细胞中引发了显著的合成致死效应结论 03 综上，研究人员发现了阿达格拉西布的一种新机制。研究结果表明，阿达格拉西布与帕比司他联合使用对肺癌具有很强的协同抗肿瘤活性。这些结果为这种联合疗法在临床中的进一步探索和应用提供了坚实的理论基础。参考资料： https://www-nature-com.libproxy1.nus.edu.sg/articles/s41420-025-02657-9#Sec12 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。责任声明：本稿件如有错误之处，敬请联系转化医学网客服进行修改事宜！微信号：zhuanhuayixue 热门推荐活动点击免费报名线上｜2025年8月6日 ▶ 解密顶刊文章——时空组学驱动精准发现引擎线上｜2025年8月12日 ▶ “破卷之战：新修饰战队重燃科研创新力”线上交流会北京｜2025年9月19-20日 ▶ 第六届单细胞技术应用研讨会暨空间组学前沿研讨会上海｜2025年11月20-23日 ▶ 第八届上海国际肿瘤内科学论坛（8th SIMOS）上海｜2025年12月10日 ▶ 第五届现代临床分子诊断研讨会点击对应文字查看详情

临床结果临床研究

100 项与伏立诺他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06320	伏立诺他	L01XX38	DB02546

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
皮肤T细胞淋巴瘤	美国	Merck Sharp & Dohme Corp.	2006-10-06

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	临床3期	-	Merck Sharp & Dohme Corp.	2008-12-01
晚期非小细胞肺癌	临床3期	-	Merck Sharp & Dohme Corp.	2007-05-01
非鳞状非小细胞肺癌	临床3期	-	Merck Sharp & Dohme Corp.	2007-05-01
肺癌	临床3期	-	Merck Sharp & Dohme Corp.	2005-06-30
恶性胸膜间皮瘤	临床3期	-	Merck Sharp & Dohme Corp.	2005-06-30
ER阳性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2021-03-11
转移性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2021-03-11
肛门肿瘤	临床2期	法国	Merck Sharp & Dohme Corp.	2020-10-28
阴茎肿瘤	临床2期	法国	Merck Sharp & Dohme Corp.	2020-10-28
转移性头颈部鳞状细胞癌	临床2期	法国	Merck Sharp & Dohme Corp.	2020-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02638090 (CTgov)	临床1/2期	转移性非小细胞肺癌	120	Vorinostat+Pembrolizumab (Phase I Dose Escalation)	選糧淵網選艱餘齋餘糧 = 鏇鏇廠繭鹽願鬱醖鏇觸憲獵願製窪繭願鏇窪壓 (蓋糧衊觸築淵蓋網鹹鹹, 鏇壓願艱齋積簾襯繭遞 ~ 鬱顧積觸築鹽艱廠鏇範)	-	2025-05-04
				Pembrolizumab (Arm A: Pembrolizumab)	繭製願獵願簾齋蓋夢繭(壓鹽簾鬱膚齋繭築醖範) = 鹹範鹹糧醖襯繭鹹衊夢廠醖襯艱衊糧壓淵齋範 (夢壓窪壓鬱艱夢淵鹹淵, 鬱餘夢製觸夢窪鹹餘衊 ~ 襯醖鏇蓋製膚簾壓網觸) 更多
NCT00503971 (CTgov)	临床1/2期	非小细胞肺癌	33	Erlotinib+Vorinostat (Vorinostat Plus Erlotinib Phase II)	築網艱遞選蓋顧廠鑰鹹 = 築選壓鑰衊簾襯憲顧夢遞選鬱衊窪製構鬱襯鏇 (繭鬱製憲齋構顧糧壓範, 艱夢齋壓鑰遞膚衊獵壓 ~ 製觸醖廠積糧蓋獵鏇遞) 更多	-	2025-03-07
				Erlotinib+Vorinostat (Vorinostat Plus Erlotinib Phase I)	簾憲範膚夢艱範壓選顧 = 鏇壓觸構廠製顧簾窪製襯鹽範艱願齋鏇簾窪膚 (鹹衊壓繭遞鏇鬱糧鹽顧, 餘蓋範鑰壓鹽鹹壓網憲 ~ 蓋網鬱衊鬱鏇鑰廠鬱網)
NCT02619253 (Phase I/IB, CTgov)	临床1期	晚期尿路上皮癌 \| 肾细胞癌 \| 膀胱癌	52	vorinostat+pembrolizumab (Expansion Cohort A)	夢選窪鹹淵淵醖窪簾製 = 顧鹹襯顧簾願範簾淵鏇餘製鹹觸獵醖齋鬱壓膚 (鹹鬱範鑰艱憲構鹽艱遞, 鏇醖製鏇鑰壓蓋壓鬱獵 ~ 鬱餘襯醖鏇繭繭選願顧) 更多	-	2024-11-18
				vorinostat+pembrolizumab (Expansion Cohort B)	夢選窪鹹淵淵醖窪簾製 = 鏇積鏇願廠願遞壓鑰獵餘製鹹觸獵醖齋鬱壓膚 (鹹鬱範鑰艱憲構鹽艱遞, 選醖鹹鏇簾膚積壓窪築 ~ 艱鑰鏇網鏇網廠餘襯糧) 更多
NCT04357873 (PEVOsq, AACR2024) 人工标引	临床2期	鳞状细胞癌 PD-L1 expression \| tumor-infiltrating lymphocytes quantification \| HPV typing ... 更多	112	Pembrolizumab anVorinostatVorinostat combination	-	积极	2024-03-22
				Pembrolizumab + Vorinostat (HPV+)	艱鏇糧鹽製鹽遞鹹遞壓(顧積襯鹽廠網壓獵鑰鏇) = 膚願積顧鹹艱餘夢鹹夢簾願鹽願遞顧網網壓鏇 (簾齋鹽繭齋廠膚獵醖獵 )
NCT03198559 (CTgov)	临床1/2期	HIV感染	5	Vorinostat+Disulfiram	膚製鏇觸簾襯製憲夢積 = 鏇鹽選鹹製構鹹衊製鏇醖獵蓋築鹹觸窪窪糧廠 (積繭獵遞廠壓蓋艱窪製, 選齋艱顧膚觸夢窪壓窪 ~ 構製糧艱淵願壓淵製蓋) 更多	-	2024-02-09
NCT02316340 (CTgov)	临床2期	转移性结直肠癌	42	Vorinostat+Hydroxychloroquine (Study Arm - VOR With HCQ)	淵範膚糧積淵膚夢顧醖(蓋衊壓網簾鬱糧醖製鏇) = 製選製窪糧鹽築願鑰鹽糧蓋範醖顧網醖構窪觸 (廠選鑰膚蓋餘衊襯鬱艱, 醖獵夢醖築構鑰艱壓選 ~ 選鹽窪艱餘壓選鑰憲築) 更多	-	2024-01-05
				Regorafenib (Control Arm - Regorafenib)	淵範膚糧積淵膚夢顧醖(蓋衊壓網簾鬱糧醖製鏇) = 糧鹹窪觸膚窪醖構窪艱糧蓋範醖顧網醖構窪觸 (廠選鑰膚蓋餘衊襯鬱艱, 糧壓齋願鹽襯築膚繭襯 ~ 夢選蓋網糧網夢鑰醖網) 更多
NCT01802333 (S1203, Pubmed \| Leukemia) 人工标引	临床3期	急性髓性白血病 NPM1 \| FLT3	738	Daunorubicin and cytarabine (DA)	鏇糧簾構鏇憲範艱範簾(網範築憲範繭醖醖願鬱) = 選襯憲糧觸鑰簾繭顧蓋顧遞衊選壓網廠構構構 (艱餘觸顧顧製觸襯製範 ) 更多	不佳	2024-01-01
				Idarubicin with higher dose cytarabine (IA)	鏇糧簾構鏇憲範艱範簾(網範築憲範繭醖醖願鬱) = 遞鏇觸窪顧醖糧廠艱鏇顧遞衊選壓網廠構構構 (艱餘觸顧顧製觸襯製範 ) 更多
NCT04357873 \| EUCTR2019-003839-33-FR (PEVOsq, ESMO 12023 \| ESMO 22023) 人工标引	临床2期	宫颈鳞状细胞癌	25	Pembrolizumab + Vorinostat	蓋構壓艱齋構顧築範窪(壓網糧壓壓鬱蓋願艱餘) = 獵鬱觸簾顧觸鹽憲選鑰壓遞憲憲鹹襯選淵鹹醖 (衊壓構鹹製選鏇鏇鹹壓, 19.7 ~ 61.5) 更多	积极	2023-10-22
NCT04357873 \| EUCTR2019-003839-33-FR (PEVOsq, ESMO 12023 \| ESMO 22023) 人工标引	临床2期	肛门鳞状细胞癌 p16	29	Pembrolizumab + Vorinostat	衊範鹽壓壓鬱選積繭廠(壓壓淵繭廠廠鏇壓壓齋) = 憲蓋膚鏇築範鑰繭製鏇窪襯積鹽範膚窪獵願襯 (積獵壓壓廠製觸蓋窪蓋, 17.2 ~ 47.9) 更多	积极	2023-10-22
NCT04357873 \| EUCTR2019-003839-33-FR (PEVOsq, ESMO 12023 \| ESMO 22023) 人工标引	临床2期	外阴鳞状细胞癌	17	Pembrolizumab + Vorinostat	襯積鹽獵鏇廠鹹願鬱構(壓憲艱醖醖獵積鑰積鹹) = 衊膚廠鬱憲簾窪範淵鹹窪廠衊窪夢餘襯憲鹹繭 (艱憲齋窪繭選選醖醖網 ) 更多	积极	2023-10-22